Gap finder

Search review questions

Each row is one question a systematic review asked: who, what, compared with what, and which outcome, with the effect it found and how certain that is. Words match anywhere in the field.

Population

Intervention or exposure

Comparison

Outcome

Any field or review title

Field or topic

Source

Review versions

759 questions in 57 reviews · Colorectal

current versions

No studies 91 · 12%Ungraded 12 · 1.6%Very low 209 · 27.5%Low 229 · 30.2%Moderate 160 · 21.1%High 58 · 7.6%

Ungraded means an effect was reported without a GRADE rating; it is not a gap. No studies means the review found nothing to answer the question. The six categories are a display order, not a score.

Question	Effect	Evidence	Status / GRADE
Enema plus dexamethasone vs enema alone Postoperative complication(s) · children with intussusception Management for intussusception in children (2017) · Cochrane	no estimate extracted	NR	No studies
Air enema vs liquid enema Successfully reduced intussusception · children with intussusception Management for intussusception in children (2017) · Cochrane	RR 1.28 [1.1, 1.49]	2 studies · 199 participants	Low
Air enema vs liquid enema Bowel perforation(s) · children with intussusception Management for intussusception in children (2017) · Cochrane	no estimate extracted	NR	No studies
Air enema vs liquid enema Recurrence of intussusception ( · children with intussusception Management for intussusception in children (2017) · Cochrane	no estimate extracted	NR	No studies
Air enema vs liquid enema Bowel resection · children with intussusception Management for intussusception in children (2017) · Cochrane	no estimate extracted	NR	No studies
Air enema vs liquid enema Postoperative complication(s) · children with intussusception Management for intussusception in children (2017) · Cochrane	no estimate extracted	NR	No studies
Enema plus glucagon vs enema alone Bowel perforation(s) · children with intussusception Management for intussusception in children (2017) · Cochrane	no estimate extracted	NR	No studies
Enema plus glucagon vs enema alone Recurrent intussusception ( · children with intussusception Management for intussusception in children (2017) · Cochrane	no estimate extracted	NR	No studies
Enema plus glucagon vs enema alone Bowel resection · children with intussusception Management for intussusception in children (2017) · Cochrane	no estimate extracted	NR	No studies
Enema plus glucagon vs enema alone Postoperative complication(s) · children with intussusception Management for intussusception in children (2017) · Cochrane	no estimate extracted	NR	No studies
Enema plus dexamethasone vs enema alone Successfully reduced intussusception · children with intussusception Management for intussusception in children (2017) · Cochrane	RR 1.01 [0.92, 1.1]	2 studies · 356 participants	Low
Enema plus dexamethasone vs enema alone Bowel perforation(s) · children with intussusception Management for intussusception in children (2017) · Cochrane	RR 2.63 [0.11, 62.66]	1 study · 75 participants	Low
Enema plus dexamethasone vs enema alone Recurrent intussusception ( · children with intussusception Management for intussusception in children (2017) · Cochrane	RR 0.14 [0.03, 0.6]	2 studies · 299 participants	Low
Enema plus dexamethasone vs enema alone Bowel resection · children with intussusception Management for intussusception in children (2017) · Cochrane	RR 0.88 [0.19, 4.06]	1 study · 75 participants	Low
Modern chemotherapy regimens vs 5‐flourouracil Overall survival · people with metastatic CRC Second‐line systemic therapy for metastatic colorectal cancer (2017) · Cochrane	HR 0.69 [0.51, 0.94]	1 study · 167 participants	Moderate
Irinotecan‐based regimens vs irinotecan Overall survival · people with metastatic CRC Second‐line systemic therapy for metastatic colorectal cancer (2017) · Cochrane	HR 0.91 [0.79, 1.04]	6 studies · 2615 participants	Low
Irinotecan‐based regimens vs irinotecan Overall tumour response · people with metastatic CRC Second‐line systemic therapy for metastatic colorectal cancer (2017) · Cochrane	RR 2.87 [2.1, 3.93]	6 studies · 2577 participants	High
Irinotecan‐based regimens vs irinotecan Severe adverse effects · people with metastatic CRC Second‐line systemic therapy for metastatic colorectal cancer (2017) · Cochrane	RR 1.18 [0.96, 1.45]	6 studies · 2510 participants	Moderate
Irinotecan + oxaliplatin vs irinotecan Overall survival · people with metastatic CRC Second‐line systemic therapy for metastatic colorectal cancer (2017) · Cochrane	HR 0.78 [0.67, 0.9]	1 study · 627 participants	Moderate
Irinotecan + oxaliplatin vs irinotecan Progression‐free survival · people with metastatic CRC Second‐line systemic therapy for metastatic colorectal cancer (2017) · Cochrane	HR 0.6 [0.55, 0.66]	1 study · 627 participants	Moderate
Irinotecan + oxaliplatin vs irinotecan Overall tumour response · people with metastatic CRC Second‐line systemic therapy for metastatic colorectal cancer (2017) · Cochrane	RR 2.98 [1.91, 4.64]	1 study · 627 participants	Moderate
Irinotecan + oxaliplatin vs irinotecan Severe adverse effects · people with metastatic CRC Second‐line systemic therapy for metastatic colorectal cancer (2017) · Cochrane	RR 1.22 [1.09, 1.37]	1 study · 627 participants	Moderate
Chemotherapy vs best supportive care Overall survival · people with metastatic CRC Second‐line systemic therapy for metastatic colorectal cancer (2017) · Cochrane	HR 0.58 [0.43, 0.8]	1 study · 279 participants	Moderate
Chemotherapy vs best supportive care Progression‐free survival · people with metastatic CRC Second‐line systemic therapy for metastatic colorectal cancer (2017) · Cochrane	no estimate extracted	NR	No studies
Chemotherapy vs best supportive care Overall tumour response · people with metastatic CRC Second‐line systemic therapy for metastatic colorectal cancer (2017) · Cochrane	no estimate extracted	NR	No studies
Modern chemotherapy regimens vs 5‐flourouracil Progression‐free survival · people with metastatic CRC Second‐line systemic therapy for metastatic colorectal cancer (2017) · Cochrane	HR 0.59 [0.49, 0.73]	2 studies · 470 participants	High
Chemotherapy vs best supportive care Severe adverse effects · people with metastatic CRC Second‐line systemic therapy for metastatic colorectal cancer (2017) · Cochrane	RR 1.19 [1.01, 1.4]	1 study · 279 participants	Moderate
FOLFIRI + targeted therapy vs FOLFIRI Overall survival · people with metastatic CRC Second‐line systemic therapy for metastatic colorectal cancer (2017) · Cochrane	HR 0.84 [0.77, 0.91]	6 studies · 3335 participants	High
FOLFIRI + targeted therapy vs FOLFIRI Progression‐free survival · people with metastatic CRC Second‐line systemic therapy for metastatic colorectal cancer (2017) · Cochrane	HR 0.78 [0.71, 0.87]	6 studies · 3335 participants	High
FOLFIRI + targeted therapy vs FOLFIRI Overall tumour response · people with metastatic CRC Second‐line systemic therapy for metastatic colorectal cancer (2017) · Cochrane	RR 2.07 [1.31, 3.28]	6 studies · 3192 participants	Moderate
FOLFIRI + targeted therapy vs FOLFIRI Severe adverse effects · people with metastatic CRC Second‐line systemic therapy for metastatic colorectal cancer (2017) · Cochrane	RR 1.3 [1.17, 1.45]	6 studies · 3341 participants	Moderate
FOLFOX + targeted therapy vs FOLFOX Overall survival · people with metastatic CRC Second‐line systemic therapy for metastatic colorectal cancer (2017) · Cochrane	HR 0.92 [0.82, 1.04]	2 studies · 1432 participants	Very low
FOLFOX + targeted therapy vs FOLFOX Progression‐free survival · people with metastatic CRC Second‐line systemic therapy for metastatic colorectal cancer (2017) · Cochrane	HR 0.76 [0.66, 0.86]	2 studies · 1432 participants	Low
FOLFOX + targeted therapy vs FOLFOX Overall tumour response · people with metastatic CRC Second‐line systemic therapy for metastatic colorectal cancer (2017) · Cochrane	RR 2.64 [1.71, 4.06]	1 study · 578 participants	Moderate
FOLFOX + targeted therapy vs FOLFOX Severe adverse effects · people with metastatic CRC Second‐line systemic therapy for metastatic colorectal cancer (2017) · Cochrane	RR 1.2 [1.13, 1.28]	2 studies · 1414 participants	High
Irinotecan + targeted therapy vs irinotecan Overall survival · people with metastatic CRC Second‐line systemic therapy for metastatic colorectal cancer (2017) · Cochrane	HR 0.99 [0.88, 1.1]	2 studies · 1758 participants	Low
Modern chemotherapy regimens vs 5‐flourouracil Overall tumour response · people with metastatic CRC Second‐line systemic therapy for metastatic colorectal cancer (2017) · Cochrane	RR 2.96 [1.66, 5.27]	3 studies · 866 participants	High
Irinotecan + targeted therapy vs irinotecan Progression‐free survival · people with metastatic CRC Second‐line systemic therapy for metastatic colorectal cancer (2017) · Cochrane	HR 0.71 [0.64, 0.79]	2 studies · 1758 participants	Moderate
Irinotecan + targeted therapy vs irinotecan Overall tumour response · people with metastatic CRC Second‐line systemic therapy for metastatic colorectal cancer (2017) · Cochrane	RR 3.38 [2.53, 4.52]	2 studies · 1758 participants	High
Irinotecan + targeted therapy vs irinotecan Severe adverse effects · people with metastatic CRC Second‐line systemic therapy for metastatic colorectal cancer (2017) · Cochrane	RR 1.44 [1.31, 1.59]	2 studies · 1704 participants	High
Modern chemotherapy regimens vs 5‐flourouracil Severe adverse effects · people with metastatic CRC Second‐line systemic therapy for metastatic colorectal cancer (2017) · Cochrane	RR 1.39 [1.22, 1.58]	3 studies · 843 participants	Moderate
Chemotherapy + bevacizumab vs chemotherapy Overall survival · people with metastatic CRC Second‐line systemic therapy for metastatic colorectal cancer (2017) · Cochrane	HR 0.79 [0.7, 0.88]	4 studies · 1723 participants	High
Chemotherapy + bevacizumab vs chemotherapy Progression‐free survival · people with metastatic CRC Second‐line systemic therapy for metastatic colorectal cancer (2017) · Cochrane	HR 0.67 [0.6, 0.75]	4 studies · 1723 participants	High
Chemotherapy + bevacizumab vs chemotherapy Overall tumour response · people with metastatic CRC Second‐line systemic therapy for metastatic colorectal cancer (2017) · Cochrane	RR 1.72 [1.23, 2.43]	4 studies · 1723 participants	High
Chemotherapy + bevacizumab vs chemotherapy Severe adverse effects · people with metastatic CRC Second‐line systemic therapy for metastatic colorectal cancer (2017) · Cochrane	RR 1.07 [0.93, 1.25]	4 studies · 1708 participants	Low
Irinotecan‐based regimens vs irinotecan Progression‐free survival · people with metastatic CRC Second‐line systemic therapy for metastatic colorectal cancer (2017) · Cochrane	HR 0.68 [0.6, 0.76]	6 studies · 2615 participants	Moderate
Intervention NR Progression‐free survival · people with metastatic colorectal cancer ‐ KRAS exon 2 WT Epidermal growth factor receptor (EGFR) inhibitors for metastatic colorectal cancer (2017) · Cochrane	HR 0.7 [0.6, 0.82]	12 studies · 4402 participants	High
Intervention NR Overall survival · people with metastatic colorectal cancer ‐ KRAS exon 2 MT Epidermal growth factor receptor (EGFR) inhibitors for metastatic colorectal cancer (2017) · Cochrane	HR 1.03 [0.94, 1.13]	8 studies · 2268 participants	High
Intervention NR Tumour response rate · people with metastatic colorectal cancer ‐ KRAS exon 2 MT Epidermal growth factor receptor (EGFR) inhibitors for metastatic colorectal cancer (2017) · Cochrane	OR 0.93 [0.74, 1.16]	8 studies · 1925 participants	High
Intervention NR Overall grade 3 to 4 toxicity · people with metastatic colorectal cancer ‐ KRAS exon 2 MT Epidermal growth factor receptor (EGFR) inhibitors for metastatic colorectal cancer (2017) · Cochrane	OR 1.63 [0.98, 2.71]	5 studies · 1635 participants	Very low